Kraig Biocraft Laboratories Leverages New Production Center for Largest Ever Batch of Spider Silk Parental Lines
Kraig Biocraft Laboratories (OTCQB: KBLB) has launched its largest production cycle of the BAM-1 spider silk line, more than doubling its previous single-batch caterpillar production record. The company is leveraging its new production rearing center to maximize capacity. The batch is divided into two groups:
1. 20% BAM-1 hybrids for reeling finished silk
2. 80% split evenly between two BAM-1 parental lines for crossbreeding
This strategy aims to quickly ramp up first-generation BAM-1 hybrid egg production. The record-setting cycle demonstrates Kraig Labs' commitment to scaling up production of advanced silk materials, positioning the company to meet diverse market needs and move closer to full-scale commercial production.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha avviato il suo più grande ciclo produttivo della linea di seta di ragno BAM-1, superando di più del doppio il precedente record di produzione in un singolo lotto di bruchi. L'azienda sta sfruttando il suo nuovo centro di allevamento per massimizzare la capacità. Il lotto è suddiviso in due gruppi:
1. 20% di ibridi BAM-1 per il riporto della seta finita
2. 80% suddiviso equamente tra due linee parentali BAM-1 per l'incrocio
Questa strategia mira ad aumentare rapidamente la produzione di uova ibride di prima generazione BAM-1. Il ciclo record dimostra l'impegno di Kraig Labs nel scalare la produzione di materiali di seta avanzati, posizionando l'azienda per soddisfare diverse esigenze di mercato e avvicinarsi a una produzione commerciale su larga scala.
Kraig Biocraft Laboratories (OTCQB: KBLB) ha lanzado su mayor ciclo de producción de la línea de seda de araña BAM-1, superando más del doble de su anterior récord de producción por lote de orugas. La empresa está aprovechando su nuevo centro de cría para maximizar la capacidad. El lote se divide en dos grupos:
1. 20% híbridos BAM-1 para hilar seda terminada
2. 80% dividido equitativamente entre dos líneas parentales BAM-1 para el cruce
Esta estrategia tiene como objetivo aumentar rápidamente la producción de huevos híbridos de primera generación BAM-1. El ciclo récord demuestra el compromiso de Kraig Labs de aumentar la producción de materiales de seda avanzados, posicionando a la empresa para satisfacer diversas necesidades del mercado y acercarse a una producción comercial a gran escala.
Kraig Biocraft Laboratories (OTCQB: KBLB)는 BAM-1 거미줄 라인의 최대 생산 주기를 시작했으며, 이전의 단일 배치 애벌레 생산 기록을 두 배 이상 초과했습니다. 회사는 용량 극대화를 위해 새로운 생산 사육 센터를 활용하고 있습니다. 이 배치는 두 그룹으로 나뉩니다:
1. 완성된 실크를 뽑기 위한 20% BAM-1 하이브리드
2. 교배를 위해 두 BAM-1 모계 라인 간에 고르게 분할된 80%
이 전략은 1세대 BAM-1 하이브리드 알 생산을 신속하게 증가시키는 것을 목표로 합니다. 기록적인 사이클은 Kraig Labs가 첨단 실크 소재 생산을 확대하는 데 전념하고 있음을 보여주며, 다양한 시장 수요를 충족하고 전체 상업 생산에 더 가까워지도록 회사를 위치시킵니다.
Kraig Biocraft Laboratories (OTCQB: KBLB) a lancé son plus grand cycle de production de la ligne de soie de araignée BAM-1, plus que doublant son précédent record de production par lot de chenilles. L'entreprise exploite son nouveau centre d'élevage pour maximiser sa capacité. Le lot est divisé en deux groupes :
1. 20 % d'hybrides BAM-1 pour le filage de soie finie
2. 80 % répartis également entre deux lignées parentales BAM-1 pour le croisement
Cette stratégie vise à augmenter rapidement la production d'œufs hybrides de première génération BAM-1. Le cycle record démontre l'engagement de Kraig Labs envers l'expansion de la production de matériaux en soie avancés, positionnant l'entreprise pour répondre aux divers besoins du marché et se rapprocher d'une production commerciale à grande échelle.
Kraig Biocraft Laboratories (OTCQB: KBLB) hat seinen größten Produktionszyklus der BAM-1-Spinnenseidenlinie gestartet und den vorherigen Rekord der Einzelbatchproduktion von Räupen mehr als verdoppelt. Das Unternehmen nutzt sein neues Produktionsaufzuchtzentrum, um die Kapazität zu maximieren. Die Charge ist in zwei Gruppen aufgeteilt:
1. 20% BAM-1-Hybriden zur Herstellung von fertiger Seide
2. 80% gleichmäßig auf zwei BAM-1-Elterlinien verteilt für die Kreuzung
Diese Strategie zielt darauf ab, die Produktion von Eiern der ersten Generation von BAM-1-Hybriden schnell zu steigern. Der rekordverdächtige Zyklus zeigt das Engagement von Kraig Labs, die Produktion fortschrittlicher Seidenmaterialien zu erhöhen, und positioniert das Unternehmen, um vielfältigen Marktbedürfnissen gerecht zu werden und näher an die vollumfängliche kommerzielle Produktion heranzutreten.
- Largest ever production cycle of BAM-1 line, more than doubling previous record
- Expanded capacity through new production rearing center
- Strategic focus on parental lines to rapidly increase first-generation hybrid egg production
- Positioning for full-scale commercial production of spider silk materials
- None.
ANN ARBOR, Mich., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company" or "Kraig Labs"), the leading developer of commercially viable spider silk, today proudly announces the launch of its largest production cycle of its BAM-1 line. Leveraging the expanded capacity of its new production rearing center, this rearing cycle will more than double the Company's previous single-batch caterpillar production record.
To grow production capacity and maximize the new rearing center, the Company has divided this batch into two groups. Twenty percent of this batch are BAM-1 hybrids for reeling finished silk. Eighty percent of this batch is split evenly between the two BAM-1 parental lines that will be crossbred to produce millions of BAM-1 hybrid silkworm eggs for future production cycles.
First-generation hybrids are created by crossbreeding the two BAM-1 parental lines together. These first-generation hybrids create larger production cocoons, increased robustness, and improved reeling performance. As such, the Company maintains a small population of its BAM-1 parental lines that are raised in parallel with the BAM-1 hybrids each production cycle. The priority placed on BAM-1 parental lines for this rearing cycle was explicitly targeted to quickly ramp up first-generation BAM-1 hybrid eggs.
This record-setting production cycle highlights the Company's ongoing commitment to scaling up the production of its advanced silk materials, bringing Kraig Labs one step closer to revolutionizing the performance materials market.
This production batch marks a significant increase in both the volume and scale of the Company's silkworm-based spider silk manufacturing, ensuring that Kraig Labs is well-positioned to meet the needs of these broad and diverse markets.
"This milestone BAM-1 production run exemplifies our commitment to scaling the production of our unique spider silk fibers," said Company Founder and CEO, Kim Thompson. "As we continue to break new ground in performance materials, this expanded capacity represents a key advancement toward full-scale commercial production."
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com
FAQ
What is the significance of Kraig Biocraft Laboratories' latest BAM-1 production cycle?
How is Kraig Biocraft Laboratories (KBLB) leveraging its new production rearing center?
What is the purpose of Kraig Biocraft Laboratories' focus on BAM-1 parental lines in this production cycle?
How does this production cycle impact Kraig Biocraft Laboratories' (KBLB) commercial prospects?
